INAB
In8bioยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
INAB Profile
In8bio, Inc.
A clinical-stage biopharmaceutical company that focused on gamma-delta T cell product candidates for solid and liquid tumors
350 5th Avenue, Suite 5330 , New York, New York 10118
--
In8 bio, Inc., was incorporated in Bermuda on February 8, 2016. On May 7, 2018, the company was reincorporated into the United States in a transaction in which the company was transformed into a newly formed Delaware company, a clinical-stage biotechnology company focused on the discovery, development and commercialization of gamma-delta T cell candidates for solid and liquid tumors.
